Snoring and Sleep Surgery: questions and answers

In detail

Obstructive sleep apnoea is characterised by recurrent complete and partial upper airway obstructive events resulting in intermittent hypoxemia and sleep fragmentation. The evaluation identifies whether obstruction occurs at the soft palate, tongue base, nasal passages, or multiple levels simultaneously.

Evidence shows OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, and atrial fibrillation.

Drug-induced sleep endoscopy replicates sleep with propofol infusion to visualise the pattern of collapse, distinguishing flat anterior-posterior collapse from concentric collapse, which affects treatment eligibility. The assessment also considers body mass index, age, and comorbid conditions such as cardiovascular disease and metabolic syndrome.

In detail

Obstructive sleep apnoea is often underrecognised and undertreated. Approximately 34% and 17% of middle-aged men and women respectively meet diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults.

Only a fraction of subjects with AHI >5 report daytime sleepiness, and studies show no relationship between daytime sleepiness and sleep apnoea in some women. Cardiovascular guidelines recommend screening for OSA in patients with resistant hypertension, pulmonary hypertension, and recurrent atrial fibrillation.

Patients with nocturnally occurring angina, myocardial infarction, arrhythmias, or appropriate ICD shocks may be especially likely to have comorbid sleep apnoea. The presence of metabolic syndrome also indicates very high prevalence of moderate to severe OSA.

In detail

OSA is independently associated with increased cardiovascular mortality. Several cohort studies consistently show this association independent of obesity. Patients with tachy-brady syndrome, ventricular tachycardia, or survivors of sudden cardiac death in whom sleep apnoea is suspected should be evaluated urgently.

After stroke, clinical equipoise exists regarding screening and treatment timing. Patients with New York Heart Association class II to IV heart failure and suspicion of sleep-disordered breathing need prompt assessment.

The mean apnoea-hypopnoea index in severe cases can exceed 30 events per hour, causing significant intermittent hypoxemia and autonomic fluctuation that may trigger acute cardiac events.

In detail

Guidelines recommend polysomnography for patients with significant cardiorespiratory disease, potential respiratory muscle weakness, awake hypoventilation, chronic opioid use, history of stroke, or severe insomnia.

Home sleep apnoea testing with a technically adequate device may be used for uncomplicated adults with signs of moderate to severe OSA. If a single home test is negative, inconclusive, or technically inadequate, polysomnography is performed.

A split-night protocol may be used during polysomnography when clinically appropriate. If clinical suspicion remains after a negative polysomnogram, a second study can be considered.

Drug-induced sleep endoscopy replicates sleep with propofol infusion to identify flat anterior-posterior or concentric palate collapse, which determines surgical eligibility, especially for hypoglossal nerve stimulation.

In detail

Evidence shows CPAP significantly reduces snoring and daytime sleepiness and improves quality of life. However, 40-60% of patients fail or are intolerant to CPAP.

For moderate to severe OSA with AHI 15-65, BMI 35 or less, and less than 25% central apnoeas, hypoglossal nerve stimulation is an option if CPAP fails. Concentric collapse on DISE excludes hypoglossal stimulation.

UPPP addresses retropalatal obstruction; nasal surgery improves CPAP compliance; tongue base reduction targets tongue collapse. Multilevel surgery combines approaches for multilevel collapse. Follow-up sleep testing assesses treatment effectiveness. The median AHI at 12 months decreased 68% from 29.3 to 9.0 events per hour in stimulation studies.

• The median AHI at 12 months decreased 68% from 29.3 to 9.0 events per hour in stimulation studies.

In detail

All patients with OSA should be considered for treatment including behavioural modifications and weight loss. CPAP should be offered for severe OSA. Oral appliances can be considered for mild to moderate OSA or CPAP-intolerant patients.

Surgical modification of pharyngeal soft tissues or facial skeleton can enlarge the upper airway. UPPP removes excess soft palate, uvula, and sometimes tonsils. Radiofrequency ablation stiffens and reduces tissue volume. Nasal surgery improves airflow and CPAP compliance.

Hypoglossal nerve stimulation uses an implantable neurostimulator activating the hypoglossal nerve during sleep. Candidates are those who failed or are not candidates for CPAP or dental device, age above 22, AHI 15-65, BMI 35 or less, and no concentric collapse. The STAR trial showed median AHI decreased 68% at 12 months. Five-year follow-up showed enduring results.

• The STAR trial showed median AHI decreased 68% at 12 months.

In detail

Weight loss and exercise are effective treatments for OSA. Positional therapy and avoiding alcohol or sedatives may help. CPAP significantly reduces snoring and daytime sleepiness and improves quality of life. Oral appliances are an alternative for mild-to-moderate OSA.

Observation alone may suit very mild asymptomatic cases, but follow-up sleep testing is needed to assess progression. These non-surgical measures are tried before surgery is recommended.

In detail

Evidence shows surgical intervention for OSA is usually recommended when CPAP or oral appliance therapy fails to provide sufficient symptom relief. Failure or intolerance of CPAP therapy occurs in 40 to 60 percent of patients.

Anatomical upper airway obstruction from structural abnormalities contributes to obstruction during sleep. Multilevel airway collapse identified on sleep endoscopy is an indication when non-surgical options fail. Patients with craniofacial abnormalities such as jaw or skeletal deformities may need maxillomandibular advancement.

Morbid obesity with BMI 35 or higher and persistent OSA despite weight loss attempts or CPAP use may warrant surgery. Severe OSA with life-threatening symptoms such as severe nocturnal desaturations, cardiac arrhythmias, or right heart strain also indicates surgery. Refractory snoring with sleep-disordered breathing limited to the soft palate region may be treated with UPPP or palate implants.

In detail

Soft palate procedures such as UPPP or radiofrequency ablation involve tissue healing that typically takes two to three weeks; patients usually notice reduced snoring and better airflow once the throat swelling resolves. Nasal surgery like septoplasty or turbinate reduction follows a similar recovery.

For hypoglossal nerve stimulation, evidence shows the device is activated about one month after surgery and settings are adjusted over the next month, with a titration sleep study to fine-tune efficacy. In studies, the apnoea-hypopnoea index decreased significantly by 12 months. Individual response varies based on anatomy, body mass index, and adherence to post-operative care.

In detail

After soft palate or nasal surgery, temporary swelling can mask the final result for several weeks; however, persistent obstruction beyond the expected healing period may indicate residual tissue collapse or scarring.

For hypoglossal nerve stimulation, the device is activated one month post-operatively and titrated over the following month; if the apnoea-hypopnoea index remains elevated after titration, the stimulation parameters may need adjustment or additional procedures considered.

Evidence shows that in studies the median AHI decreased by 68% at 12 months, but individual outcomes vary. Weight gain, alcohol use, or untreated nasal allergy can also limit improvement. A follow-up sleep study is the standard way to objectively assess treatment effectiveness.

• Evidence shows that in studies the median AHI decreased by 68% at 12 months, but individual outcomes vary.

In detail

Evidence links OSA with excessive daytime sleepiness, reduced cognitive function, and higher motor vehicle crash risk, all of which can affect work and driving. Successful treatment, whether by CPAP, oral appliance, or surgery, typically improves alertness and productivity.

After soft palate or nasal surgery, throat discomfort and a soft diet may limit physical exertion for two to three weeks; hypoglossal nerve stimulation requires a longer initial recovery of four to six weeks before full activity.

The implantable device is safe for airport security scanners, but you should carry the device identification card. Weight loss and regular exercise are recommended as part of long-term management and can further reduce apnoea severity. Your surgeon will give specific guidance based on your procedure and occupation.

In detail

Diagnosis relies on recognised classification criteria that include symptom patterns, physical signs, and laboratory abnormalities. Common blood tests include antinuclear antibody (ANA), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), extractable nuclear antigens (ENA), and disease-specific antibodies such as anti-dsDNA for lupus or ANCA for vasculitis.

Inflammation markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) support the presence of active inflammation but are not specific. Imaging such as ultrasound or MRI may show joint erosions or organ involvement. The specialist excludes infections, malignancies, and other mimics before confirming an autoimmune diagnosis.

In detail

Each antibody has a different diagnostic weight. For example, anti-CCP is highly specific for rheumatoid arthritis, while anti-dsDNA is more specific for systemic lupus erythematosus. ANA is sensitive but not specific; a positive result can occur in infections, medications, or healthy individuals.

ENA panels help differentiate overlap syndromes. CRP and ESR rise with inflammation from any cause, including infection or injury, so they are used to track disease activity and treatment response rather than to diagnose. Serial measurements over time are more informative than a single value. Your rheumatologist correlates these results with clinical findings to guide therapy.

In detail

Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, biologics targeting specific immune pathways, and corticosteroids each play a role. Corticosteroids give rapid symptom control but do not alter disease progression when used alone.

Conventional DMARDs and biologics modify the underlying immune process, slowing or halting structural damage seen on imaging. Evidence shows that tight control strategies targeting remission improve long-term function and reduce disability. Treatment plans are individualised based on disease type, severity, organ involvement, and patient factors. Regular monitoring with clinical assessment, blood tests, and imaging ensures the therapy is preventing damage, not just masking symptoms.

In detail

Corticosteroids are bridging therapy; they reduce inflammation quickly while slower agents take effect, but long-term use carries risks of osteoporosis, diabetes, and infection.

Conventional synthetic DMARDs (csDMARDs) such as methotrexate, sulfasalazine, and hydroxychloroquine are first-line for many rheumatic diseases; they modify disease progression and are monitored with regular blood counts and liver tests.

Biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are reserved for inadequate response to csDMARDs; they block specific cytokines or cells, offering higher remission rates but requiring screening for tuberculosis, hepatitis, and vaccination updates before starting. Cost, route of administration, and side-effect profiles differ. Your rheumatologist selects the regimen based on disease type, severity, comorbidities, and patient preference.

In detail

Methotrexate and leflunomide require monthly blood counts and liver tests initially, then every three months. Biologics need periodic monitoring for infection and malignancy risk.

Live vaccines such as MMR, varicella and yellow fever are contraindicated during significant immunosuppression; inactivated vaccines including influenza, pneumococcal, COVID-19 and hepatitis B are recommended. Tuberculosis screening with interferon-gamma release assay or Mantoux test is mandatory before anti-TNF therapy. Your specialist coordinates the schedule based on your regimen.

In detail

Many medicines cross the placenta and can affect the baby, especially in the first trimester when organs are forming. Your doctor will weigh the benefit of each medicine against any known risk.

For example, certain sedatives, muscle relaxants, or blood pressure drugs may have safer alternatives. If you use continuous positive airway pressure (CPAP) for obstructive sleep apnoea, that therapy is generally continued during pregnancy because untreated apnoea can reduce oxygen supply to the baby.

The hospital's pulmonology and gynaecology teams can work together to adjust your plan. Evidence shows that all patients with obstructive sleep apnoea should be considered for treatment, including behavioural modifications and weight loss as indicated, and CPAP can mitigate risks.

In detail

Obstructive sleep apnoea can worsen over time, especially with weight gain, alcohol use, or sedating medicines. A flare may show as louder snoring, witnessed apnoeas, unrefreshing sleep, or rising blood pressure.

Serious medicine side effects depend on the drug but can include allergic rash, difficulty breathing, abnormal heart rhythm, severe dizziness, or unusual bleeding. Evidence indicates that obstructive sleep apnoea is associated with increased risk of cardiovascular events, stroke, hypertension, and coronary artery disease.

If you use CPAP and symptoms return, the pressure may need adjustment or the mask may be leaking. Any new neurological symptom such as weakness or speech change needs immediate evaluation.

In detail

The decision starts with a clinical history, examination of the upper airway, and a sleep study (polysomnography or home sleep apnoea test) to confirm obstructive sleep apnoea and its severity.

Evidence shows that surgical intervention for obstructive sleep apnoea is usually recommended when non-surgical treatments such as CPAP or oral appliance therapy fail to provide sufficient symptom relief, and that 40 to 60 percent of patients fail or are intolerant to CPAP.

If the sleep study confirms moderate to severe apnoea and you cannot use CPAP, or if drug-induced sleep endoscopy shows a correctable anatomical collapse, surgery may be offered.

Options include uvulopalatopharyngoplasty, radiofrequency ablation, nasal surgery, tongue base reduction, or hypoglossal nerve stimulation, depending on the site and pattern of obstruction.

In detail

DISE uses a short infusion of propofol to replicate natural sleep while a flexible endoscope visualises the palate, tongue base, and lateral walls.

Evidence shows that patients who are candidates for hypoglossal nerve stimulation first undergo DISE to determine the pattern of collapse of the palate, and that concentric collapse at the palate predicts lower success with stimulation.

The procedure helps the surgeon choose the right operation — whether palate surgery, tongue base reduction, nasal correction, or nerve stimulation — by showing the level and pattern of obstruction. It is done as a day-case under monitored anaesthesia care.

In detail

Evidence indicates that UPPP has been the mainstay of treatment for obstructive sleep apnoea for decades, but long-term success varies and lack of enduring outcomes has been a concern.

The procedure removes or stiffens excess tissue of the soft palate, uvula, and sometimes tonsils to widen the airway. Radiofrequency ablation offers a less invasive option to stiffen the palate.

Success depends on careful patient selection: those with isolated retropalatal collapse and a favourable anatomy tend to do better. If collapse also occurs at the tongue base or lateral walls, palate surgery alone may not control the apnoea. Your surgeon will discuss realistic expectations based on your anatomy and sleep study results.

In detail

Evidence shows OSA is a breathing disorder during sleep. Nasal surgery can improve nasal breathing and CPAP compliance. Palate surgery (UPPP) may cause temporary velopharyngeal insufficiency, leading to nasal regurgitation or hypernasal speech for a few weeks. Tongue base reduction can cause short-term swallowing discomfort.

Hypoglossal nerve stimulation does not alter speech or swallowing. Hearing and balance are not affected by these procedures. The team monitors recovery closely.

In detail

These symptoms may indicate infection, tumour, nerve injury, or structural problems that need timely treatment. For example, sudden sensorineural hearing loss is a medical emergency where early steroids can improve recovery.

A persistent neck lump in an adult warrants imaging and possible biopsy to rule out malignancy. Chronic hoarseness may reflect vocal cord lesions or reflux. Stridor suggests airway narrowing that can become life-threatening.

Evidence shows that obstructive sleep apnoea is associated with considerable health risks, and untreated upper airway obstruction can worsen. If you have known sleep apnoea and develop new upper airway symptoms, they may signal disease progression or a treatment complication.

In detail

Price variation reflects the complexity of the operation. UPPP, radiofrequency ablation, septoplasty or turbinate reduction fall in the lower range. Hypoglossal nerve stimulation includes the implantable pulse generator, sensing lead and stimulation electrode, which account for most of the higher cost.

Hospital stay is usually one to two nights for palate or nasal procedures and may be longer for device implantation. Anaesthesia, operating theatre time, nursing care and routine investigations are included. The hospital works with RGHS, MAA Yojana, CGHS and private insurers; coverage varies by policy.

In detail

The estimate includes the surgeon's fee, theatre time, anaesthesia charges and standard ward accommodation.

Items that are often billed separately are pre-operative investigations such as polysomnography or drug-induced sleep endoscopy, specialist consultations, any implants or devices, higher-category room upgrades, medicines taken home, and follow-up visits after discharge. The final bill depends on the exact procedure chosen and any additional services you use.